Ocugen, Inc. Q3 2026 Financial Results and Business Highlights - OCUGEN INC

Explicit Guidance:

• Cash Runway: Current cash, equivalents, restricted cash, and short-term investments of $84.6 million (as of Sept 30, 2026) are expected to support operations into 2028.
• BLA Filings: On track to file three Biologics License Applications (BLAs) by 2028.
• Share Count: 339.3 million shares outstanding as of Sept 30, 2026; no specific guidance on future share count changes provided.
• No explicit revenue, earnings, or margin guidance was issued for FY2026, FY2027, or FY2028.

Business-Segment Outlook:

• OCU-400 (Retinitis Pigmentosa): Enrollment of 140 patients completed in Phase III "Limelight" trial; top-line data anticipated in Q1 2027; BLA submission planned immediately following readout.
• OCU-410-ST (Stargardt Disease): Pivotal Phase 2/3 "Guardian" trial ongoing; interim analysis concluded with recommendation to continue without modification; top-line data anticipated in Q2 2027; BLA submission follows.
• OCU-410 (Geographic Atrophy): Phase III "Armada 3" trial initiated with first patient dose in September 2026 (237 subjects across US, Canada, Europe); enrollment targeted for completion in 2027; BLA filing targeted for 2028.
• International Expansion: Established European presence for pre-commercial activities; secured exclusive license for OCU-400 in Middle East and North Africa (MENA) with Roots Pharmaceuticals (up to $4M upfront/initial milestones + $255M development milestones + 22% royalty); executing regulatory pathway in Bahamas for potential patient enrollment as early as year-end 2026 under LARTA.

Market and Competitive Outlook:

• Geographic Atrophy (GA): OCU-410 aims to displace existing therapies requiring ongoing intrauterine injections (up to monthly) with a single, one-time injection addressing multiple disease pathways.
• Stargardt Disease: Addresses a pediatric-onset condition with no currently approved therapies; anticipated 25% reduction in lesion growth required for statistical significance (conservative benchmark vs. 54% observed in Phase 1/2).
• Retinitis Pigmentosa (RP): Projected responder rate of at least 71.4% (5 of 7 subjects) in Phase 1/2 data meeting Phase III thresholds; Phase III powered to detect difference even at a hypothetical 20% responder rate (93.2% power) compared to 1% control.
• Competitive Advantage: Emphasis on gene-agnostic, multifactorial platform capability to restore balance across multiple gene networks compared to single-mutation or single-pathway competitors.

Macro / Industry Outlook:

• Regulatory Strategy: Leveraging alternative regulatory frameworks (e.g., Bahamas LARTA) to enable earlier patient access and commercial revenue generation prior to US approval.
• Industry Trend: Moving towards one-time gene therapies offering durable benefit over chronic treatment regimens.
• No explicit commentary on interest rates, FX rates, tariffs, or broader macroeconomic conditions was provided.

Strategic Initiatives:

• Licensing & Partnerships: Finalized binding term sheet for OCU-400 in MENA with Roots Pharmaceuticals (announced July, finalized October); building on prior agreement with Kwong Dong Pharmaceutical in South Korea.
• Commercial Infrastructure: Establishing European presence to support development and commercialization without building local infrastructure in every market; relying on regional partners for non-US scale.
• Patient Access Programs: Executing agreement with Global Alliance for Regenerated Medicine to coordinate patient care in Bahamas; conditional provisional approval expected to convert to full approval by year-end 2026.
• Manufacturing: Process performance qualification batches for OCU-400 completed, supporting both BLA and commercial launch supply.

Risks and Headwinds to Outlook:

• Clinical Trial Uncertainty: Reliance on positive Phase III results for BLA filings; specific risks include heterogeneity in baseline characteristics (noted in Stargardt interim analysis) and the time required for gene therapy transgene suppression to manifest effects.
• Regulatory & Access Delays: Dependence on foreign regulatory approvals (Bahamas) for early commercialization; potential delays in full lot approvals or site readiness could impact "year-end" enrollment targets.
• Data Interpretation: Interim analyses are not efficacy analyses; decisions rely on full cohort data at month 12 (Stargardt) and month 52 (RP) to normalize baseline differences.
• Standard Disclaimer: Actual results may differ materially due to risks, uncertainties, and assumptions inherent in clinical development, regulatory timelines, and financial projections.

Management Tone on the Future:

• Confidence Level: High confidence in clinical design and data; reiterated "clear strategy" and "execution" focus.
• Catalyst Focus: Prioritizing near-term catalysts, specifically OCU-400 data in Q1 2027 and OCU-410-ST data in Q2 2027.
• Strategic Shift: Transitioning from pure clinical development to commercial readiness and international expansion (Europe, Bahamas, MENA).
• Forward-Looking Statement: "We remain on track to deliver three BLAs over the next three years."

Miscellaneous:

• Financial Metrics: No specific guidance provided on R&D or G&A spending ratios for 2027-2028 beyond the current burn rate supporting the 2028 runway.
• Pricing Model: Bahamas program pricing expected to match US/international commercial pricing levels under local regulatory structures.
• Study Design: OCU-410 Armada 3 is a 237-subject, 2-to-1 randomized study with a primary endpoint of GA lesion growth over 12 months.